 MaxCyte Inc. has set terms for its initial public offering, in which the Maryland-based cell engineering company could be valued at up to 1.31 billion. The company is looking to raise up to 162.0 million, as it is offering 12.0 million shares in the IPO, which is expected to price between 11.50 and 13.50 a share. 